TY - JOUR
T1 - Secondary Stroke Prevention in Polish Adults
T2 - Results from the LIPIDOGRAM2015 Study
AU - Labuz-Roszak, Beata
AU - Banach, Maciej
AU - Skrzypek, Michal
AU - Windak, Adam
AU - Tomasik, Tomasz
AU - Mastej, Miroslaw
AU - Tomaszewski, Maciej
AU - Mikhailidis, Dimitri P.
AU - Toth, Peter P.
AU - Catapano, Alberico
AU - Ray, Kausik K.
AU - Howard, George
AU - Lip, Gregory Y. H.
AU - Charchar, Fadi J.
AU - Sattar, Naveed
AU - Williams, Bryan
AU - Macdonald, Thomas M.
AU - Penson, Peter
AU - Jozwiak, Jacek J.
N1 - Funding Information:
Funding: The present study was an initiative of the Polish Lipid Association (PoLA) and the College of Family Physician in Poland (CFPiP). The present study was funded by an unrestricted educational grant from Valeant. As a supporter of the study, Valeant had no role in study design, data analysis, data interpretation, or writing of the report. The present study was also supported by Silesian Analytical Laboratories (SLA), CHDE, BIO‐RAD.
Publisher Copyright:
© 2021 by the authors.
PY - 2021/10
Y1 - 2021/10
N2 - Background: The purpose of the study was to evaluate secondary stroke prevention in Poland and its association with sociodemographic factors, place of residence, and concomitant cardiovascular risk factors.Material and methods: From all patients in LIPIDOGRAM2015 Study (n = 13,724), 268 subjects had a history of ischaemic stroke and were included. Results: 165 subjects (61.6%) used at least one preventive medication. Oral antiplatelet and anticoagulation agents were used by 116 (43.3%) and 70 (26.1%) patients, respectively. Only 157 (58.6%) participants used lipid-lowering drugs, and 205 (76.5%) were treated with antihypertensive drugs. Coronary heart disease (CHD) and dyslipidaemia were associated with antiplatelet treatment (p = 0.047 and p = 0.012, respectively). A history of atrial fibrillation, CHD, and previous myocardial infarction correlated with anticoagulant treatment (p = 0.001, p = 0.011, and p < 0.0001, respectively). Age, gender, time from stroke onset, place of residence, and level of education were not associated with antiplatelet or anticoagulant treatment. Only 31.7% of patients were engaged in regular physical activity, 62% used appropriate diet, and 13.6% were current smokers.Conclusions: In Poland drugs and lifestyle modification for secondary stroke prevention are not commonly adhered to. Educational programmes for physicians and patients should be developed to improve application of effective secondary prevention of stroke.
AB - Background: The purpose of the study was to evaluate secondary stroke prevention in Poland and its association with sociodemographic factors, place of residence, and concomitant cardiovascular risk factors.Material and methods: From all patients in LIPIDOGRAM2015 Study (n = 13,724), 268 subjects had a history of ischaemic stroke and were included. Results: 165 subjects (61.6%) used at least one preventive medication. Oral antiplatelet and anticoagulation agents were used by 116 (43.3%) and 70 (26.1%) patients, respectively. Only 157 (58.6%) participants used lipid-lowering drugs, and 205 (76.5%) were treated with antihypertensive drugs. Coronary heart disease (CHD) and dyslipidaemia were associated with antiplatelet treatment (p = 0.047 and p = 0.012, respectively). A history of atrial fibrillation, CHD, and previous myocardial infarction correlated with anticoagulant treatment (p = 0.001, p = 0.011, and p < 0.0001, respectively). Age, gender, time from stroke onset, place of residence, and level of education were not associated with antiplatelet or anticoagulant treatment. Only 31.7% of patients were engaged in regular physical activity, 62% used appropriate diet, and 13.6% were current smokers.Conclusions: In Poland drugs and lifestyle modification for secondary stroke prevention are not commonly adhered to. Educational programmes for physicians and patients should be developed to improve application of effective secondary prevention of stroke.
KW - Oral anticoagulant drugs
KW - Oral antiplatelet drugs
KW - Primary health care
KW - Secondary stroke prevention
UR - http://www.scopus.com/inward/record.url?scp=85116380632&partnerID=8YFLogxK
U2 - 10.3390/jcm10194472
DO - 10.3390/jcm10194472
M3 - Article
C2 - 34640490
AN - SCOPUS:85116380632
SN - 2077-0383
VL - 10
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 19
M1 - 4472
ER -